NASDAQ:BEAM Beam Therapeutics Q2 2025 Earnings Report $20.60 -0.95 (-4.41%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$20.61 +0.01 (+0.05%) As of 09/12/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Beam Therapeutics EPS ResultsActual EPS-$1.00Consensus EPS -$1.04Beat/MissBeat by +$0.04One Year Ago EPS-$1.11Beam Therapeutics Revenue ResultsActual Revenue$8.47 millionExpected Revenue$13.29 millionBeat/MissMissed by -$4.83 millionYoY Revenue Growth-28.00%Beam Therapeutics Announcement DetailsQuarterQ2 2025Date8/5/2025TimeBefore Market OpensConference Call DateTuesday, August 5, 2025Conference Call Time7:00AM ETUpcoming EarningsBeam Therapeutics' Q3 2025 earnings is scheduled for Tuesday, November 4, 2025, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Beam Therapeutics Earnings HeadlinesBeam Therapeutics (BEAM): Assessing Valuation After Strategic Shift and Analyst Optimism on BEAM-302 ProgramSeptember 14 at 4:18 PM | finance.yahoo.comBeam Therapeutics Inc. (BEAM) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)September 9, 2025 | seekingalpha.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.September 14 at 2:00 AM | Porter & Company (Ad)Beam Therapeutics Inc. (BEAM) Presents At H.C. Wainwright 27th Annual Global Investment Conference TranscriptSeptember 9, 2025 | seekingalpha.comBeam Therapeutics (NASDAQ:BEAM) Raised to Hold at Wall Street ZenSeptember 8, 2025 | americanbankingnews.comBernstein Issues a Buy Rating on Beam Therapeutics (BEAM)September 7, 2025 | theglobeandmail.comSee More Beam Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Beam Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Beam Therapeutics and other key companies, straight to your email. Email Address About Beam TherapeuticsBeam Therapeutics (NASDAQ:BEAM), Inc. (NASDAQ: BEAM) is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need. Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R. Liu, Ph.D., and a team of genome-editing pioneers. Unlike traditional CRISPR/Cas9 approaches that create double-strand DNA breaks, Beam’s base editing platform converts one DNA letter into another through targeted enzymatic reactions, minimizing genomic disruption. The company’s pipeline includes ex vivo programs for monogenic blood disorders such as sickle cell disease and beta thalassemia, as well as in vivo candidates aimed at rare metabolic and genetic conditions. Strategic collaborations with major pharmaceutical partners support the translation of these programs into clinical development. Since its initial public offering in early 2020, Beam Therapeutics has expanded its capabilities in research, development and manufacturing, forging partnerships to scale delivery and production of its novel editors. The company’s leadership team brings together seasoned executives and scientists with expertise in protein engineering, lipid nanoparticle delivery and regulatory strategy, all united by a commitment to advance next-generation precision therapies. As Beam progresses key programs toward clinical milestones, it remains focused on translating base editing innovations into safe and effective treatments for patients worldwide.View Beam Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles RH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a WinnerWhat to Watch for From D-Wave Now That Earnings Are Done Upcoming Earnings FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025)Fastenal (10/13/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
